Bian Fang, Cui Jun, Zheng Tao, Jin Si
Department of Pharmacy, The Affiliated Hospital of Xiangyang Central Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441000, P.R. China.
Department of Cardiothoracic Surgery, The Affiliated Hospital of Xiangyang Central Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441000, P.R. China.
Int J Mol Med. 2017 Mar;39(3):629-635. doi: 10.3892/ijmm.2017.2887. Epub 2017 Feb 13.
The retention of plasma low-density lipoprotein (LDL) particles to subendothelial spaces through transcytosis across the endothelium is the initial step of atherosclerosis (AS). Angiotensin II (Ang II), as the principal effector molecule of the renin-angiotensin system (RAS), is implicated in several important steps of AS development. However, whether or not Ang II can directly exert a pro‑atherogenic effect by promoting LDL transcytosis across endothelial barriers, has not been defined. In the present study, we found that Ang II upregulated intracellular reactive oxygen species (ROS) levels in endothelial cells (ECs) by measuring fluorescence of 2',7'-dichlorofluorescein (DCF‑DA). Based on our transcytosis model, we observed that Ang II significantly accelerated LDL transcytosis, whereas transcytosis inhibitor methyl-β-cyclodextrin (MβCD) and ROS inhibitor dithiothreitol (DTT), markedly blocked the Ang II-stimulated increase in LDL transcytosis. Confocal imaging analysis revealed that both LDL uptake by cells and LDL retention in human umbilical venous walls were highly elevated after Ang II exposure, while MβCD and DTT significantly inhibited the effects of Ang II. What is more, proteins involved in caveolae-mediated transcytosis, including LDL receptor (LDLR), caveolin-1 and cavin-1, were associated with Ang II-induced LDL transcytosis across the ECs. Nevertheless, this process was independent of clathrin in our study. Of note, ROS inhibitor, DTT, markedly decreased the expression levels of those proteins. Consequently, ROS are critical mediators in Ang II-induced LDL transcytosis. Hopefully, these findings will provide novel insight into the crosstalk between dyslipidemia and RAS in atherogenesis.
血浆低密度脂蛋白(LDL)颗粒通过跨内皮细胞的转胞吞作用滞留于内皮下间隙是动脉粥样硬化(AS)的起始步骤。血管紧张素II(Ang II)作为肾素-血管紧张素系统(RAS)的主要效应分子,参与AS发展的多个重要步骤。然而,Ang II是否能通过促进LDL跨内皮屏障的转胞吞作用直接发挥促动脉粥样硬化作用,尚未明确。在本研究中,我们通过检测2',7'-二氯荧光素(DCF-DA)的荧光发现,Ang II上调了内皮细胞(ECs)内活性氧(ROS)水平。基于我们的转胞吞模型,我们观察到Ang II显著加速了LDL的转胞吞作用,而转胞吞抑制剂甲基-β-环糊精(MβCD)和ROS抑制剂二硫苏糖醇(DTT)显著阻断了Ang II刺激的LDL转胞吞作用增强。共聚焦成像分析显示,Ang II处理后细胞对LDL的摄取及LDL在人脐静脉壁中的滞留均显著增加,而MβCD和DTT显著抑制了Ang II的作用。此外,参与小窝介导的转胞吞作用的蛋白,包括LDL受体(LDLR)、小窝蛋白-1和小窝装配蛋白-1,均与Ang II诱导的LDL跨ECs转胞吞作用有关。然而,在我们的研究中,这一过程不依赖网格蛋白。值得注意的是,ROS抑制剂DTT显著降低了这些蛋白的表达水平。因此,ROS是Ang II诱导LDL转胞吞作用的关键介质。希望这些发现将为动脉粥样硬化发生过程中血脂异常与RAS之间的相互作用提供新的见解。